Printable: Should the cost of Revlimid (lenalidomide) be reduced?

Should the cost of Revlimid (lenalidomide) be reduced? (https://www.myeloma.org/videos/should-cost-revlimid-lenalidomide-be-reduced)

In this week’s video, Dr. Brian G.M. Durie addresses why the cost of patented drugs, such as Revlimid, have not yet been reduced.

BOTTOM LINE:
The cost of drugs is important to all of the myeloma community, and the IMF will continue to take part in discussing this.

Author

Dr. Brian GM Durie (https://www.myeloma.org/Brian-Durie-md)

Video

Series

Ask Dr. Durie (https://www.myeloma.org/taxonomy/term/19)

Old Id

781

Ask a Question

Please note that Ask Dr. Durie has been discontinued, and it was designed to address myeloma questions of the broadest possible audience interest. If you have a question of a personal nature, please contact our InfoLine Coordinators at 800.452.2873 or [email protected] (mailto:[email protected]) (Please do not send email attachments or lab reports.).

Image of Dr. Brian G.M. Durie Dr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.